Similarly, upregulation of PD‐L1 or CD8+ T cells in rectal cancer patients after neoadjuvant CRT has been reported,16 suggesting the potential for a combined application of cytotoxic therapy and ICIs. The gene discussed is CD8A; the disease is rectal cancer.